Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192907 | 1.00 | CES2 (1.00) | CES2MAPTRXFP1TAAR1NPC1 | |
| SCHEMBL24013409 | 0.85 | CES2 (0.74) | CES2TAAR1NPC1GAARAB9A | |
| SCHEMBL4437059 | 0.85 | CES2 (0.74) | CES2MAPTRXFP1TAAR1NPC1 | |
| SCHEMBL4440938 | 0.85 | CES2 (0.74) | CES2TAAR1NPC1GAARAB9A | |
| SCHEMBL15339808 | 0.85 | CES2 (0.74) | CES2TAAR1NPC1GAARAB9A | |
| SCHEMBL4437533 | 0.82 | CES2 (0.69) | CES2NPC1RAB9A | |
| SCHEMBL4443290 | 0.81 | CES2 (0.68) | CES2TAAR1NPC1GAARAB9A | |
| SCHEMBL24013513 | 0.81 | CES2 (0.67) | CES2MAPTTAAR1NPC1GAA | |
| SCHEMBL3240006 | 0.80 | CES2 (0.66) | CES2MAPTRXFP1TAAR1NPC1 | |
| SCHEMBL24013826 | 0.80 | CES2 (0.66) | CES2MAPTTAAR1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249128-B2 | Anti-cancer serine hydrolase inhibitory carbamates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-02-02 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012058115-A2 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | CRAVATT BENJAMIN (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281453-A1 | ANTI-CANCER SERINE HYDROLASE INHIBITORY CARBAMATES | AADAC, DDAH1, PRSS1 | CES2 679/4885MAPT 4221/4885RXFP1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.